Idioma:

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Sandborn, William J ; Feagan, Brian G ; Rutgeerts, Paul ; Hanauer, Stephen ; Colombel, Jean-Frédéric ; Sands, Bruce E ; Lukas, Milan ; Fedorak, Richard N ; Lee, Scott ; Bressler, Brian ; Fox, Irving ; Rosario, Maria ; Sankoh, Serap ; Xu, Jing ; Stephens, Kristin ; Milch, Catherine ; Parikh, Asit

The New England journal of medicine, 2013-08, Vol.369 (8), p.711-721 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Autor: Sandborn, William J ; Feagan, Brian G ; Rutgeerts, Paul ; Hanauer, Stephen ; Colombel, Jean-Frédéric ; Sands, Bruce E ; Lukas, Milan ; Fedorak, Richard N ; Lee, Scott ; Bressler, Brian ; Fox, Irving ; Rosario, Maria ; Sankoh, Serap ; Xu, Jing ; Stephens, Kristin ; Milch, Catherine ; Parikh, Asit
Assuntos: Adult ; Antibodies - blood ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - immunology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects/immunology/therapeutic use ; Biological and medical sciences ; Clinical trials ; Crohn Disease - drug therapy ; Crohn's disease ; Double-Blind Method ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Gastroenterology & hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastroentérologie & hépatologie ; General aspects ; Glucocorticoids - therapeutic use ; Headache ; Human health sciences ; Humans ; Immunosuppressive Agents - therapeutic use ; Induction Chemotherapy ; Induction therapy ; Inflammatory bowel disease ; Infusions, Intravenous - adverse effects ; Integrins - antagonists & inhibitors ; Integrins - immunology ; Integrins/antagonists & inhibitors/immunology ; Intravenous administration ; Maintenance Chemotherapy ; Male ; Medical research ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pain ; Pharmaceuticals ; Remission ; Rhinopharyngitis ; Sciences de la santé humaine ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Ulcers
É parte de: The New England journal of medicine, 2013-08, Vol.369 (8), p.711-721
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
scopus-id:2-s2.0-84882749768
Descrição: In this 52-week randomized trial, the α 4 β 7 integrin antibody vedolizumab was effective in treating Crohn's disease. The incidence of serious adverse events was higher with vedolizumab than with placebo. Crohn's disease is a chronic inflammatory bowel disease. 1 Current treatments include glucocorticoids, immunosuppressive agents (i.e., azathioprine, mercaptopurine, or methotrexate), and tumor necrosis factor (TNF) antagonists. 1 – 3 Many patients do not have a response to therapy, 4 and treatments are associated with important toxic effects. 5 , 6 Natalizumab, a monoclonal antibody that modulates gut and brain lymphocyte migration by antagonizing α 4 β 1 and α 4 β 7 integrin–mediated interactions, 7 is efficacious in the treatment of multiple sclerosis 8 , 9 and Crohn's disease. 10 – 12 Its use in patients with Crohn's disease has been limited by the development in some patients of progressive multifocal . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Sandborn, William J ; Feagan, Brian G ; Rutgeerts, Paul ; Hanauer, Stephen ; Colombel, Jean-Frédéric ; Sands, Bruce E ; Lukas, Milan ; Fedorak, Richard N ; Lee, Scott ; Bressler, Brian ; Fox, Irving ; Rosario, Maria ; Sankoh, Serap ; Xu, Jing ; Stephens, Kristin ; Milch, Catherine ; Parikh, Asit

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.